Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$145.35

-2.095 (-1.42%)

12:03
08/07/18
08/07
12:03
08/07/18
12:03

Sage Therapeutics continues to make progress on Zulresso, says Piper Jaffray

Sage Therapeutics continues to make progress preparing for potential FDA approval/launch of Zulresso for post partum depression, Piper Jaffray analyst Danielle Brill tells investors in a research note following the company's Q2 results. The analyst expects the FDA panel on November 2 to be supportive of approval. She reiterates an Overweight rating on Sage shares with a $206 price target.

  • 07

    Aug

SAGE Sage Therapeutics
$145.35

-2.095 (-1.42%)

06/13/18
JEFF
06/13/18
NO CHANGE
Target $9
JEFF
Buy
Sage update yesterday positive for Xenon, says Jefferies
Jefferies analyst Maury Raycroft believes Sage Therapeutics' (SAGE) FDA approval to accelerate a development path for '217 in major depressive disorder and postpartum depression provides a positive read-through for Xenon Pharmaceuticals (XENE). Xenon has two epilepsy programs and one program for hemiplegic migraine, which all have potential in rare disease indications with broader applicability, Raycroft tells investors in a research note. He believes "recent derisking" provides a "great entry point" into Xenon Pharmaceuticals at current share levels. The analyst has a Buy rating on the shares with a $9 price target.
08/06/18
PIPR
08/06/18
INITIATION
Target $206
PIPR
Overweight
Sage Therapeutics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill started Sage Therapeutics with an Overweight rating and $206 price target. The analyst thinks Sage is on course to becoming a leader in central nervous system therapeutics. Its lead compound, IV brexanolone, is on track to becoming the first FDA approved therapy for postpartum depression by the end of 2018, Brill tells investors in a research note.
08/06/18
08/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Global Blood Therapeutics (GBT) initiated with an Overweight at Piper Jaffray. 2. Welltower (WELL) reinstated with a Neutral at Goldman Sachs. 3. Sage Therapeutics (SAGE) initiated with an Overweight at Piper Jaffray. 4. SoftBank (SFTBY) initiated with a Buy at UBS. 5. Alder Biopharmaceuticals (ALDR) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/18
STFL
08/07/18
INITIATION
Target $239
STFL
Buy
Sage Therapeutics transferred with a Buy at Stifel
Stifel transferred coverage of Sage Therapeutics to analyst Paul Matteis, who set a Buy rating and $239 price target on the shares. Matteis sees a high likelihood path for SAGE-217 to become a $3B-$5B product across an array of psychiatric indications. He also expects FDA approval of Sage's brexanolone for postpartum depression by the end of this year.

TODAY'S FREE FLY STORIES

CBFV

CB Financial Services

$25.79

(0.00%)

14:42
11/21/18
11/21
14:42
11/21/18
14:42
Hot Stocks
CB Financial Services increases dividend by 4.5% to 23c per share »

CB Financial Services,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$32.94

4.87 (17.35%)

14:28
11/21/18
11/21
14:28
11/21/18
14:28
Hot Stocks
CD&R Group to buy additional shares in Beacon Roofing »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NTN

NTN Buzztime

$2.70

-0.1 (-3.57%)

14:26
11/21/18
11/21
14:26
11/21/18
14:26
Hot Stocks
Northstar reports 10.33% stake in NTN Buzztime »

On November 21, Northstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:23
11/21/18
11/21
14:23
11/21/18
14:23
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a podcast »

The Commodity Futures…

RHHBY

Roche

$0.00

(0.00%)

, ABBV

AbbVie

$85.75

-2.35 (-2.67%)

14:18
11/21/18
11/21
14:18
11/21/18
14:18
Hot Stocks
Roche announces FDA grants accelerated approval for Venclexta combo »

Roche (RHHBY) announced…

RHHBY

Roche

$0.00

(0.00%)

ABBV

AbbVie

$85.75

-2.35 (-2.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/21/18
11/21
14:17
11/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

, RHHBY

Roche

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Hot Stocks
AbbVie says FDA grants accelerated approval to Venclexta-azacitidine combo »

AbbVie (ABBV) announced…

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$54.99

1.4 (2.61%)

14:15
11/21/18
11/21
14:15
11/21/18
14:15
Periodicals
Martin Sorrell to poach senior executive from WPP, Sky News reports »

Martin Sorrell is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

TGT

Target

$69.10

0.05 (0.07%)

14:10
11/21/18
11/21
14:10
11/21/18
14:10
Options
Target calls lead puts 3:1 after a big drop in shares »

Target calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HWBK

Hawthorn Bancshares

$22.71

(0.00%)

14:08
11/21/18
11/21
14:08
11/21/18
14:08
Hot Stocks
Ategra stake in Hawthorn Bancshares falls to 4.97% »

As of November 20, Ategra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAM

I-AM Capital

$10.00

(0.00%)

14:04
11/21/18
11/21
14:04
11/21/18
14:04
Hot Stocks
I-AM Capital announces closing of transaction with SMAAASH Entertainment »

Smaaash Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

$9.60

0.23 (2.45%)

14:00
11/21/18
11/21
14:00
11/21/18
14:00
Options
Longer-term put buyer in Banco Bradesco »

Longer-term put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:56
11/21/18
11/21
13:56
11/21/18
13:56
Periodicals
Hedge funds get battered in October and are down for year, CNBC says »

According to a CNBC…

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$5.54

0.07 (1.28%)

13:50
11/21/18
11/21
13:50
11/21/18
13:50
Options
Aggressive call buy in Vipshop »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

13:50
11/21/18
11/21
13:50
11/21/18
13:50
General news
Treasury Action: yields remain only marginally firmer »

Treasury Action: yields…

PFE

Pfizer

$43.23

-0.3 (-0.69%)

13:41
11/21/18
11/21
13:41
11/21/18
13:41
Hot Stocks
Pfizer says FDA approves DAURISMO for adults with newly-diagnosed AML »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

EFA

iShares MSCI EAFE Index Fund

$62.35

1.05 (1.71%)

13:40
11/21/18
11/21
13:40
11/21/18
13:40
Options
Call buying in iShares Emerging Markets Fund and iShares MSCI EAFA Fund »

Call buying in iShares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

13:30
11/21/18
11/21
13:30
11/21/18
13:30
Options
Vix calls lead puts 4:1 as the index drops 9% »

Vix calls lead puts 4:1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$6.95

0.18 (2.66%)

13:25
11/21/18
11/21
13:25
11/21/18
13:25
Options
Akorn call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

OMED

OncoMed

$1.37

(0.00%)

13:22
11/21/18
11/21
13:22
11/21/18
13:22
Hot Stocks
OncoMed awarded European patent for method for making heteromultimeric molecules 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

, RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

13:17
11/21/18
11/21
13:17
11/21/18
13:17
Hot Stocks
Aquestive under pressure after generic Suboxone patent decision »

Shares of Aquestive…

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

MYL

Mylan

$33.29

-0.65 (-1.92%)

ENDP

Endo

$12.39

-0.14 (-1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 02

    Dec

  • 04

    Dec

  • 19

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/21/18
11/21
13:17
11/21/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/21/18
11/21
13:16
11/21/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$12.60

0.3 (2.44%)

, T

AT&T

$30.01

0.6 (2.04%)

13:15
11/21/18
11/21
13:15
11/21/18
13:15
Hot Stocks
GameStop jumps over 10% after agreeing to sell Spring Mobile unit »

Shares of GameStop (GME)…

GME

GameStop

$12.60

0.3 (2.44%)

T

AT&T

$30.01

0.6 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.